Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olverembatinib + lisaftoclax
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olverembatinib + lisaftoclax is an investigational, oral, chemotherapy-free combination regimen developed by Ascentage Pharma. Olverembatinib is a potent third-generation tyrosine kinase inhibitor (TKI) that targets BCR-ABL1 (including the T315I mutant and other resistant variants) and KIT. Lisaftoclax is a novel, selective small-molecule BCL-2 inhibitor. Together, they act synergistically to increase apoptosis and reduce anti-apoptotic proteins such as BCL-2, BCL-xL, and MCL-1. The combination is primarily being evaluated in clinical trials for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including pediatric populations, and advanced chronic myeloid leukemia (CML) or Ph+ acute myeloid leukemia (AML).
- Brand names
- LishengtuoNailike
- Other names
- APG-2575 + HQP-1351APG-2575 + HQP1351APG-2575 plus HQP1351APG2575 plus HQP1351APG 2575 plus HQP1351HQP-1351 + APG-2575HQP1351 + APG-2575HQP1351 + lisaftoclaxlisaftoclax + olverembatinibolverembatinib + APG-2575olverembatinib plus lisaftoclax
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)BCL2L1 (B-cell lymphoma-extra large protein)BCR-ABL1 (Breakpoint cluster region-Abelson tyrosine-protein kinase 1)BIMCRKL (CRK-like proto-oncogene, adaptor protein)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MCL1 (Myeloid cell leukemia sequence 1)PDGFRA (Platelet-derived growth factor receptor alpha)SFK (SRC family kinases)STAT5A (STAT5)BCL-2 (BCL-2 family)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on olverembatinib + lisaftoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olverembatinib + lisaftoclax.